Kymera Therapeutics Inc
Research Kymera Therapeutics Inc (KYMR) on Bullrun: market cap USD 10.48B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerKYMR
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 10.48B
- Financial periodQ2 2026
- RevenueUSD 65.00M
- Net income-USD 61.21M
- Free cash flow-USD 54.54M
Valuation Snapshot
latest market cap is USD 10.48B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 39.21M | USD 311.35M | -USD 234.34M | 0.0% | -3.69 | USD 357.01M | USD 82.25M | USD 1.58B |
| FY2024 | USD 47.07M | USD 223.86M | -USD 207.34M | 0.0% | -2.98 | USD 120.26M | USD 87.76M | USD 835.62M |
| FY2023 | USD 78.59M | USD 146.96M | -USD 137.31M | 0.0% | -2.52 | USD 109.97M | USD 84.67M | USD 394.97M |
| FY2022 | USD 46.83M | USD 154.81M | -USD 155.92M | 0.0% | -2.87 | USD 68.40M | USD 17.29M | USD 490.15M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 10.48B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 6.33B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.61B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.41B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.37B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 3.27B | n/a | n/a | n/a |
About Kymera Therapeutics Inc
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Kymera Therapeutics Inc's market cap?
Kymera Therapeutics Inc's market capitalization is USD 10.48B.
What does Kymera Therapeutics Inc do?
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.